/compare — side-by-sideLOADING
Valuation, growth, margins and forensic scores side-by-side — computed from each company's own SEC filings and last EOD close. No estimates, no fluff.
| Metric | UPCUniverse Pharmaceuti |
|---|---|
| Last close | no stored close |
| Change % | no stored close |
| Market cap | no stored close |
| P/E | no stored close |
| Revenue | $17.9B⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldRevenues As ofFY ending 2025-09-30 Filing20-F · 0001213900-26-009000 · filed 2026-01-29 Open the filing on EDGAR →Open the XBRL payload → |
Fundamentals from XBRL company facts (as filed); market cap & P/E use last EOD close. Each cell names its period. A ratio row reads not comparable when the companies’ periods differ by more than six weeks or mix a fiscal year with a trailing twelve months, and a figure more than a year older than the company’s newest period is marked older period. No row ranks the companies. Educational only, not investment advice.
| Rev growth (YoY) | -22.4%FY to 2025-09-30 |
| Net income | $-3672055000⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldNetIncomeLoss As ofFY ending 2025-09-30 Filing20-F · 0001213900-26-009000 · filed 2026-01-29 Open the filing on EDGAR →Open the XBRL payload →CiteUniverse Pharmaceuticals INC (UPC), us-gaap:NetIncomeLoss: -3,672,055,000 USD, fiscal year ended 2025-09-30. Form 20-F, accession 0001213900-26-009000, filed 2026-01-29. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001809616/us-gaap/NetIncomeLoss.json |
| Net margin | -20.6%FY to 2025-09-30 |
| EPS (diluted) | $-8.06⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldEarningsPerShareDiluted As ofFY ending 2025-09-30 Filing20-F · 0001213900-26-009000 · filed 2026-01-29 Open the filing on EDGAR →Open the XBRL payload →CiteUniverse Pharmaceuticals INC (UPC), us-gaap:EarningsPerShareDiluted: -8.06 USD per share, fiscal year ended 2025-09-30. Form 20-F, accession 0001213900-26-009000, filed 2026-01-29. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001809616/us-gaap/EarningsPerShareDiluted.json |
| Piotroski F-ScoreUNVALIDATED | 4FY to 2025-09-30 |
| Altman Z-ScoreUNVALIDATED | inputs not filed |
| Beneish M-ScoreUNVALIDATED | inputs not filed |
| Next earnings | — |